clinical trial · NCT03664648
DV2-HBV-27: Observational Pregnancy Registry
PregnantHEPLISAV-B
brief summary
Purpose of the study is to evaluate pregnancy outcomes among women who received a dose of HEPLISAV-B within 28 days prior to conception or at any time during pregnancy
started
Feb 21, 2021
primary completion
Sep 1, 2024
completion
Dec 1, 2024
last updated
Sep 18, 2023
official title
HEPLISAV-B Pregnancy Registry: An Observational Study on the Safety of HEPLISAV-B Exposure in Pregnant Women and Their Offspring
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol